Clover Health Comments on 2026 Medicare Advantage Star Ratings and Trajectory for Increasing Profitability into 2027

Clover Health Investments (CLOV) announced its 2026 Medicare Advantage Star ratings, receiving 3.5 Stars for its PPO plans and 4.0 Stars for its HMO plan, which will impact payment year 2027. Despite these ratings, the company reiterated confidence in its ability to drive above-market membership growth and increasing Adjusted EBITDA profitability through 2027, asserting its AI-driven Clover Assistant platform and differentiated business model can offset Star rating effects. Clover cited strong H1 2025 performance, including significant revenue and membership growth during a comparable 3.5-star payment year, and high HEDIS clinical quality scores as evidence of its model's resilience and effectiveness.

Analysis

Clover Health (CLOV) announced its 2026 Medicare Advantage Star ratings, with PPO plans receiving 3.5 Stars and HMO plans 4.0 Stars, impacting payment year 2027. Despite these ratings, the company expressed strong confidence in its differentiated business model and AI-driven Clover Assistant platform to achieve above-market membership growth and increasing Adjusted EBITDA profitability through 2027. This strategy aims to mitigate the financial impact typically associated with lower Star ratings.

The company cited robust performance in the first half of 2025, a period with comparable 3.5-star payment dynamics, demonstrating 34% year-over-year revenue growth and 32% membership expansion, alongside sustained Adjusted EBITDA profitability. Furthermore, Clover's PPO plans achieved an exceptional 4.72 HEDIS clinical quality score, largely attributed to the Clover Assistant, underscoring its clinical efficacy.

CEO Andrew Toy highlighted a belief that the current CMS Star Ratings methodology disproportionately weighs non-outcomes measures. He anticipates a future industry shift towards prioritizing actual clinical outcomes, a landscape for which Clover, with its AI roadmap and focus on physician adoption of Clover Assistant, claims to be uniquely positioned to thrive independently of current quality bonuses.

Key Decisions for Investors

• Monitor CLOV's ability to sustain its stated above-market membership growth and Adjusted EBITDA profitability through 2027, particularly given the 3.5-star PPO rating's impact on payment year 2027.
• Evaluate the ongoing impact and physician adoption of the Clover Assistant technology on clinical outcomes and cost efficiencies as a key driver of the company's differentiated strategy.
• Assess the potential for future regulatory changes to the CMS Star Ratings methodology, as anticipated by Clover, and how such shifts could re-align the company's valuation based on clinical outcomes rather than current administrative metrics.